Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Income from Continuing Operations for 7 consecutive years, with 244297000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 370.38% to 244297000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 80144000.0 through Dec 2025, up 78.36% year-over-year, with the annual reading at 79992000.0 for FY2025, 78.77% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 244297000.0 at Beam Therapeutics, up from 112728000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 244297000.0 in Q4 2025, with the low at 200394000.0 in Q1 2021.
  • Average Income from Continuing Operations over 5 years is 60285700.0, with a median of 86521000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations tumbled 621.93% in 2021, then surged 472.37% in 2023.
  • Over 5 years, Income from Continuing Operations stood at 64707000.0 in 2021, then soared by 40.75% to 38339000.0 in 2022, then soared by 472.37% to 142763000.0 in 2023, then plummeted by 163.29% to 90354000.0 in 2024, then skyrocketed by 370.38% to 244297000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 244297000.0, 112728000.0, and 102291000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.